SynAct Pharma

“SynAct kept a fast pace during the year, working hard through the end of the fourth quarter. First and foremost, the company was successfully introduced to Nasdaq Stockholm’s main market in July. The pipeline development with primary focus on our lead compound, AP1189, was further advanced, and with the acquisition of TXP Pharma the company has the possibility to build a broad pipeline to address new indications. The finances and shareholder base were bolstered with a successful rights issue of SEK 150 million and the directed share issue of SEK 80 million. With our studies progressing and this broader portfolio, SynAct is in a very good position to drive shareholder value,” said Jeppe Øvlesen, CEO of SynAct Pharma (extract from the CEO-letter).